195 related articles for article (PubMed ID: 38259002)
21. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
22. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
[TBL] [Abstract][Full Text] [Related]
23. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
[TBL] [Abstract][Full Text] [Related]
24. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Rombouts SJ; Walma MS; Vogel JA; van Rijssen LB; Wilmink JW; Mohammad NH; van Santvoort HC; Molenaar IQ; Besselink MG
Ann Surg Oncol; 2016 Dec; 23(13):4352-4360. PubMed ID: 27370653
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence.
Chaudhari VA; Mitra A; Gupta V; Ostwal V; Ramaswamy A; Engineer R; Sirohi B; Shetty N; Bal M; DeSouza A; Bhandare MS; Shrikhande SV
Surgery; 2022 May; 171(5):1388-1395. PubMed ID: 34922745
[TBL] [Abstract][Full Text] [Related]
26. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of distal pancreatectomy with celiac axis resection and sub-adventitial divestment technique for locally advanced or borderline resectable pancreatic body cancer].
Huang XM; Yin J; Lu ZP; Chen JM; Cai BB; Wu PF; Jiang KR; Miao Y
Zhonghua Wai Ke Za Zhi; 2022 May; 60(5):441-448. PubMed ID: 35359085
[No Abstract] [Full Text] [Related]
28. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
Sternby H; Andersson B
Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.
Ye M; Zhang Q; Chen Y; Fu Q; Li X; Bai X; Liang T
HPB (Oxford); 2020 Jun; 22(6):821-832. PubMed ID: 32001139
[TBL] [Abstract][Full Text] [Related]
30. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.
Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A
J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
32. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
[TBL] [Abstract][Full Text] [Related]
34. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2).
Farnes I; Kleive D; Verbeke CS; Aabakken L; Issa-Epe A; Småstuen MC; Fosby BV; Dueland S; Line PD; Labori KJ
BJS Open; 2023 Nov; 7(6):. PubMed ID: 38155512
[TBL] [Abstract][Full Text] [Related]
35. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
[TBL] [Abstract][Full Text] [Related]
36. Distal Pancreatectomy With En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Gong H; Ma R; Gong J; Cai C; Song Z; Xu B
Medicine (Baltimore); 2016 Mar; 95(10):e3061. PubMed ID: 26962836
[TBL] [Abstract][Full Text] [Related]
37. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
38. Distal pancreatectomy with En bloc celiac axis resection for locally advanced pancreatic body/tail cancer: A systematic review and meta-analysis.
Liu L; Liu TX; Huang WX; Yang Z; Wang S; Da MX; Dong Y
Asian J Surg; 2022 Jan; 45(1):51-61. PubMed ID: 34187724
[TBL] [Abstract][Full Text] [Related]
39. Assessement of postoperative long-term survival quality and complications associated with radical antegrade modular pancreatosplenectomy and distal pancreatectomy: a meta-analysis and systematic review.
Zhou Q; Fengwei-Gao ; Gong J; Xie Q; Liu Y; Wang Q; Lei Z
BMC Surg; 2019 Jan; 19(1):12. PubMed ID: 30691444
[TBL] [Abstract][Full Text] [Related]
40. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
